Although metabolomic profiling offers promise for the prediction of coronary heart disease (CHD), and metabolic risk factors are more strongly associated with CHD in women than men, limited data are available for women.
C
oronary heart disease (CHD) remains the leading cause of death in women, as in men. However, the clinical manifestations of CHD differ, with a greater preponderance of nonobstructive atherosclerosis and microvascular disease 1 and higher case fatality rates in women than in men. Metabolic risk factors, especially diabetes mellitus, are particularly strong risk factors for CHD in women. Women with type 2 diabetes mellitus have >40% higher risk of CHD than men with diabetes mellitus. 2, 3 However, data on the relationship of metabolites and CHD using metabolomic profiling have been very limited in women.
Examinations of the relationship of CHD with circulating blood metabolite levels measured using metabolomics have illuminated different potential pathways to CHD development. Incident cardiovascular disease and longevity have been associated with metabolites in the citric acid cycle and gut microbe-associated trimethylamine N-oxide, choline, and multiple lipid-related metabolites. [4] [5] [6] [7] [8] [9] [10] [11] Glutamate and glutamine have also been associated with diabetes mellitus, 12 and with cardiovascular disease in previous studies, 4, 6, 9 as have branched chain and aromatic amino acids. 12, 13 However, despite evidence of sexual dimorphism in the metabolome, 14, 15 these associations have not been examined in detail in women. Furthermore, metabolite profiles may also change during menopause, 16 a time coinciding with increased CHD risk. Therefore, the examination of metabolomics profiles in women may help to identify new metabolic associations and mechanistic pathways underlying CHD in women, which may extend also to men.
Here, we used metabolomics to identify novel metabolic signatures for incident CHD in female participants of the WHI (Women's Health Initiative), 17 with independent discovery and validation sets derived from the WHI-OS (Women's Health Initiative-Observational Study) 18 and the placebo arms of the WHI-HT (Women's Health Initiative-Hormone Trials), 19 respectively. We also performed external replication using an independent mixed sex study from the PREDIMED trial (Prevención con Dieta Mediterránea) 20, 21 to assess the generalizability of significant metabolites to cardiovascular disease and both sexes.
METHODS

This study was approved by Partners Human Research
Committee, which is the institutional review board of Brigham and Women's Hospital. Metabolite data from the discovery and validation data sets used in this study have been deposited in and are available from the dbGaP database under dbGaP accession no. phs001334.v1.p3. 22 All other data will not be made available by the authors, nor will analytic methods or study materials.
Human Studies
WHI-OS (Discovery)
The discovery set was drawn from the WHI-OS. The full WHI-OS consisted of 93 676 postmenopausal women ineligible or unwilling to participate in the related hormone trials, enrolled between 1994 and 1998 in the United States. All participants provided written informed consent. For this study, 472 participants who developed CHD after the baseline examination (cases) were selected, including all nonwhite cases with an eligible control and a sample of the white cases, and 472 participants who did not develop CHD frequency matched on 5-year age, race/ethnicity, hysterectomy status, and 2-year enrollment groups. Only 21 hormone therapy users were included in the discovery set, and use was not adjusted for, but a sensitivity analysis removing the hormone therapy users did not change the effect estimates.
WHI-HT (Validation)
The validation set was drawn from the placebo arms of the WHI-HT. One of the trials randomly assigned 16 608 postmenopausal women to estrogen plus progesterone or placebo, whereas the other 10 739 women with prior hysterectomy were randomly assigned to estrogen or placebo. All participants provided written informed consent. We selected 312 cases and 315 frequency-matched controls from the 2 placebo arms with matching on 5-year age, race/ethnicity, hysterectomy status, and 2-year enrollment window.
Clinical Perspective
What Is New?
• Using a robust design, we identified and validated 33 metabolites associated with coronary heart disease in postmenopausal women, 8 of which remained independently associated after adjustment for standard cardiovascular risk factors.
• The risk association for the novel metabolite with the strongest association (C34:2 hydroxy-phosphatidylcholine) is independent of other metabolites, improves the area under the receiver operator characteristic curve when added to standard risk factors, and replicates in an additional data set containing both men and women, and for both coronary heart disease and stroke events, as well.
• We have identified a cluster of novel metabolites related to oxidative stress, which are not strongly correlated with traditional biomarkers.
What Are the Clinical Implications?
• Identified metabolites may be useful as additional biomarkers for clinical risk assessment in addition to highlighting new areas of biological exploration and potential therapeutic targets.
• Metabolite precursors of coronary heart disease need to be studied in sufficient sample sizes of both men and women. 
PREDIMED (Replication)
The replication set was drawn from the PREDIMED trial that also used the Broad Institute metabolomics platform. The full PREDIMED trial randomly assigned men and women at high risk of developing cardiovascular disease to 1 of 3 interventions: a Mediterranean dietary intervention supplemented with virgin olive oil, a Mediterranean dietary intervention supplemented with nuts, or advice about a low-fat diet. All participants provided written informed consent. The primary end point for this trial was a composite of myocardial infarction, stroke, and cardiovascular disease (CVD) death. For this study, a case-cohort design as outlined by Prentice 23 was used, which included all 230 cases (74 myocardial infarctions, 115 strokes, and 31 CVD deaths) and a random 10% sample of participants at baseline (787 participants). Of the 787 subcohort participants, 37 had a primary end point during follow-up (and thus were also included in the 230 cases), whereas 750 did not, resulting in 980 unique participants for analysis.
Metabolomics
Plasma samples were collected using EDTA tubes in the WHI and PREDIMED cohorts and processed immediately. All WHI specimens were stored in a -70°C freezer within 2 hours of collection or stored at -20°C for up to 2 days and shipped on dry ice and stored at -70°C until processing. The majority of the WHI samples had been thawed once before our study, with 7 samples (6 cases and 1 control) having been thawed twice. PREDIMED samples were shipped at -4°C, and then stored at -70°C until analysis. Metabolomic measurements were made using 4 complimentary liquid chromatography-tandem mass spectroscopy (LC-MS) methods resulting in 371 metabolites for the WHI samples. Only the hydrophilic interaction liquid chromatography (HILIC)-positive and C8-positive methods were available in the PREDIMED samples. For each method, pooled plasma reference samples were included every 20 samples, and results were standardized using the ratio of the value of the sample to the value of the nearest pooled reference multiplied by the median of all reference values for the metabolite.
HILIC analyses of water-soluble metabolites in the positive ionization mode (HILIC-pos) were conducted using an LC-MS system composed of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp) coupled to a Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher Scientific). Plasma samples (10 μL) were prepared via protein precipitation with the addition of 9 volumes of 74.9:24.9:0.2 v/v/v acetonitrile/ methanol/formic acid containing stable isotope-labeled internal standards (valine-d8, Sigma-Aldrich; and phenylalanined8, Cambridge Isotope Laboratories). The samples were centrifuged (10 minutes, 9000g, 4°C), and the supernatants were injected directly onto a 150×2 mm, 3-μm Atlantis HILIC column (Waters). The column was eluted isocratically at a flow rate of 250 μL/min with 5% mobile phase A (10 mmol/L ammonium formate and 0.1% formic acid in water) for 0.5 minute followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. Mass spectroscopic (MS) analyses were performed by using electrospray ionization in the positive ion mode using full scan analysis over 70 to 800 m/z at 70 000 resolution and 3 Hz data acquisition rate. Other MS settings were as follows:
sheath gas 40, sweep gas 2, spray voltage 3.5 kV, capillary temperature 350°C, S-lens RF 40, heater temperature 300°C, microscans 1, automatic gain control target 1e6, and maximum ion time 250 ms.
HILIC analyses of water-soluble metabolites in the negative ionization mode (HILIC-neg) were conducted by using an LC-MS system composed of an AQUITY UPLC system (Waters and a 5500 QTRAP mass spectrometer [SCIEX] ). Plasma samples (30 μL) were prepared via protein precipitation with the addition of 4 volumes of 80% methanol containing inosine-15N4, thymine-d4, and glycocholate-d4 internal standards (Cambridge Isotope Laboratories). The samples were centrifuged (10 minutes, 9000g, 4°C), and the supernatants were injected directly onto a 150×2.0 mm Luna NH2 column (Phenomenex). The column was eluted at a flow rate of 400 μL/min with initial conditions of 10% mobile phase A (20 mmol/L ammonium acetate and 20 mmol/L ammonium hydroxide in water) and 90% mobile phase B (10 mmol/L ammonium hydroxide in 75:25 v/v acetonitrile/methanol) followed by a 10-minute linear gradient to 100% mobile phase A. MS analyses were performed using electrospray ionization and selective multiple reaction monitoring scans in the negative ion mode. To create the method, declustering potentials and collision energies were optimized for each metabolite by infusion of reference standards. The ion spray voltage was -4.5 kV and the source temperature was 500°C.
Positive ion mode analyses of polar and nonpolar plasma lipids (C8-pos) were conducted by using an LC-MS system composed of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp) coupled to a Exactive Plus orbitrap mass spectrometer (Thermo Fisher Scientific). Plasma samples (10 μL) were extracted for lipid analyses using 190 μL of isopropanol containing 1,2-didodecanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids). After centrifugation, supernatants were injected directly onto a 100×2.1 mm, 1.7-μm ACQUITY BEH C8 column (Waters). The column was eluted isocratically with 80% mobile phase A (95:5:0.1 v/v/v 10 mmol/L ammonium acetate/methanol/formic acid) for 1 minute followed by a linear gradient to 80% mobile phase B (99.9:0.1 v/v methanol/ formic acid) over 2 minutes, a linear gradient to 100% mobile phase B over 7 minutes, then 3 minutes at 100% mobile phase B. MS analyses were performed using electrospray ionization in the positive ion mode using full scan analysis over 200 to 1000 m/z at 70 000 resolution and 3 Hz data acquisition rate. Other MS settings were as follows: sheath gas 50, in source collision-induced dissociation 5 eV, sweep gas 5, spray voltage 3 kV, capillary temperature 300°C, S-lens RF 60, heater temperature 300°C, microscans 1, automatic gain control target 1e6, and maximum ion time 100 ms. Lipid identities were determined based on comparison with reference plasma extracts and were denoted by the total number of carbons in the lipid acyl chain(s) and total number of double bonds in the lipid acyl chain(s).
Negative ion mode analyses of free fatty acids and bile acids (C18-neg) were conducted using an LC-MS system composed of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp) coupled to a Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher Scientific). Plasma samples (30 μL) were extracted using 90 μL of methanol containing PGE2-d4 (Cayman Chemical Co) and centrifuged (10 minutes, 9000g, February 20, 2018 Circulation. 
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4°C). The samples were injected onto a 150×2 mm ACQUITY T3 column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 400 μL/min with 60% mobile phase A (0.1% formic acid in water) for 4 minutes followed by a linear gradient to 100% mobile phase B (acetonitrile with 0.1% formic acid) over 8 minutes. MS analyses were performed in the negative ion mode using electrospray ionization, full scan MS acquisition over 200 to 550 m/z, and a resolution setting of 70 000. Metabolite identities were confirmed using authentic reference standards. Other MS settings were as follows: sheath gas 45, sweep gas 5, spray voltage -3.5 kV, capillary temperature 320°C, S-lens RF 60, heater temperature 300°C, microscans 1, automatic gain control target 1e6, and maximum ion time 250 ms. Raw data from Q Exactive/Exactive Plus instruments were processed using TraceFinder software (Thermo Fisher Scientific) and Progenesis QI (Nonlinear Dynamics), whereas MultiQuant (SCIEX) was used to process 5500 QTRAP data. For each method, metabolite identities were confirmed using authentic reference standards or reference samples. Coefficients of variation (CVs) were calculated using pooled plasma samples from the first 800 WHI-OS participants.
Statistical Analysis
Two sets of covariates were used in WHI analyses. The first set included the frequency matching factors (age, race/ethnicity, hysterectomy status, and enrollment window). The second set included the matching factors plus traditional CHD risk factors (smoking, systolic blood pressure, diabetes mellitus, total and high-density lipoprotein cholesterol) and CHD medication use (aspirin, statins, antihyperglycemics, and antihypertensives). All metabolites were scaled and log-normalized, and missing values below the limit of detection were assigned to half the lowest observed value. R was used for all analyses with packages noted below.
Discovery Methods
For the discovery analysis in the WHI-OS, each metabolite was examined individually in logistic models including both sets of covariates. Statistically significant associations satisfied false discovery rate-adjusted P<0.05 using the 2-stage step-up procedure: 24 this procedure allows for dependencies between the metabolites and is implemented using the corresponding TSBH option of the mt.rawp2adjp function in the multtest package with a nominal α of 0.05. Unconditional logistic regression was chosen over conditional to improve the precision of estimates while still controlling for the frequencymatching factors. 25 
Validation Methods
Metabolite associations with CHD discovered in WHI-OS were validated in the independent WHI-HT data set. Metabolites were examined individually using the same covariate sets used for discovery; thus, a metabolite that was selected in the discovery process, when adjusted for matching factors but not when adjusted for additional risk factors, would only be validated with adjustment for matching factors. Metabolite associations were considered to have been validated if the false discovery rate-adjusted P value (same procedure as discovery) for the odds ratio after adjustment was <0.05 and the nominal P value was <0.025.
Area Under the Curve Calculation
By combining data from the parent WHI cohort with the data generated in the matched case-control study, we estimated the prediction score for each subject by using methods described by Qian and colleagues. 26 To estimate the receiver operating characteristics curve and associated area under the curve, we reweighted our sample to account for the frequency-matched selection of cases and controls from the source populations in the WHI. We used 1000 bootstrap samples that preserved the frequency matching to construct the confidence interval for the difference in the area under the curve comparing models with and without C34:2 hydroxyphosphatidylcholine (hydroxy-PC) in addition to matching and other risk factors.
Derived Networks
A correlation network was generated by using the full WHI data set in which nodes represent individual metabolites and edges between node pairs indicate a partial correlation (adjusting for case status) that exceeded 0.7 in magnitude. This procedure resulted in a network of 371 nodes and 1256 edges. The connected components of the partial correlation network were identified by using the clusters function in the R igraph package. Fisher's exact tests were then used to test whether each connected set of metabolites included more validated metabolites associated with CHD than expected by chance.
Enantomeric Composition
The reversed phase separation used in the LC-MS method to profile the WHI data set does not distinguish stereoisomers. Therefore, enantiomeric purity was investigated using chiral chromatography following the method of Oh et al. 27 LC-MS tracings for representative samples from the WHI data set were compared with enantiomerically pure standards, and a racemic mixture. An Agilent 4695 mass spectrometer was used to measure the characteristic negative ion mode 319.2/115.1 transition at a collision energy setting of 13.
Replication Methods
Four metabolites from the 2 available metabolomics platforms in PREDIMED were examined individually in weighted Cox proportional hazards models, adjusting for age, sex, intervention group, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, smoking, and statin use. The weighting method of Barlow et al 28 was used to account for the random, nonstratified sampling design along with the exact case-cohort pseudolikelihood estimators with robust variance estimators, as proposed by Langholz and Jiao 29 for the Cox proportional hazards models. Metabolite associations were considered to have been replicated if the P value for the hazard ratio was <0.05. Interaction P values were determined by using the Wald test for the interaction coefficient.
RESULTS
The baseline characteristics of the 944 women in the WHI-OS discovery set (472 cases and 472 controls) and the 627 women in the WHI-HT validation set (312 cases and 315 controls) are shown in ORIGINAL RESEARCH ARTICLE was similar in both sets. The median time to CHD event for the cases, defined as myocardial infarction or death attributable to CHD, was 5.8 years in the discovery set and 3.7 years in the validation set. A total of 371 metabolites of known identity were profiled using LC-MS with a median CV of 6.28%, as measured in replicate quality-control pooled plasma samples included throughout the analyses. The relationship between individual metabolites and CHD was assessed by using logistic regression controlling for matching variables only or matching variables plus CHD risk factors. In the discovery set, 60 of the 371 metabolites were identified as significant (false discovery rate P<0.05) controlling for matching variables alone, and 36 (17 also identified in the matching analysis) were identified controlling for matching plus CHD risk factors. Results of the discovery analysis are shown in Table I in the online-only Data Supplement.
All metabolites discovered when controlling for matching variables were then tested in a separate validation set of 627 women from the placebo arms of WHI-HT (312 cases and 315 controls), and 33 were significantly associated with CHD (false discovery rate P<0.05, nominal P<0.025). Similarly, 8 of the 36 metabolites discovered with adjustment for matching plus CHD risk factors remained significant in the independent validation data set. Table 2 presents the results only for validated metabolites; the results for all discovered metabolites can be found in Table II in the online-only Data Supplement. Of the 8 metabolites that were significantly associated with CHD after adjustment for traditional CHD risk factors, 7 were associated with increased risk: C34:2 hydroxy-PC, C36:4 hydroxy-PC, 5-hydroxyeicosatetraenoic acid (HETE), 15-HETE, 11-HETE, glutamate, and cytidine monophosphate. A single metabolite, glutamine, was associated with decreased risk of CHD. Associations between the 8 metabolites and other biomarkers and CHD risk factors are shown in Figure 1 . It is noteworthy that none of the oxidized lipid metabolites (C34:2 hydroxy-PC, C36:4 hydroxy-PC, 5-HETE, 15-HETE, and 11-HETE) were correlated with C-reactive protein, lipoprotein(a), or Lipoprotein-associated phospholipase A2 activity or mass. CV and percentage of samples with values below the limit of detection for validated metabolites are provided in Table III in the online-only Data Supplement.
When the 8 validated metabolites were mutually adjusted for in models controlling for matching factors and CHD risk factors, only C34:2 hydroxy-PC remained significantly associated with CHD case status in the WHI. Women in the highest quartile of C34:2 hydroxy-PC had 4.69 (95% confidence interval, 2.84-7.90) times the odds of CHD in comparison with those in the lowest quartile. The relationship between C34:2 hydroxy-PC and CHD remained consistent across sub- groups of baseline characteristics as shown in Figure 2 . To evaluate the impact on prediction of CHD, we estimated the prediction score by integrating metabolomics data from the matched case-control study to existing data on risk factors available for the full WHI cohort. 26 We estimated the area under the receiver operator characteristic curve by incorporating inverse probability weights to reweight the distribution of risk 
01).
To identify connections between validated metabolites, a correlation network of the 371 metabolites was constructed by using all metabolite pairs. Edges between metabolite pairs were drawn to indicate an absolute Spearman partial correlation coefficient exceeding 0.7, while adjusting for case status. An enrichment analysis was layered on the partial correlation network to discover clusters of connected (correlated) metabolites that are enriched for associations with CHD. Six clusters included validated metabolites, and, of these, only 1 cluster, shown in Figure 3 , contained significantly more validated metabolites than would be expected by chance (P=3.185E-07). Each node in this cluster was an oxidized lipid, including 2 hydroxy-PCs and 4 HETEs, 3 of which were validated after full adjustment for risk factors and one of which (12-HETE) was validated with adjustment for matching factors only.
To determine whether the mono-HETEs associated with CHD were generated by enzymatic activity (single isomers) or nonenzymatic oxidation of arachidonic acid (racemic mixture), we analyzed stereoisomers of 5-HETE by using chiral chromatography. As shown in Figure 4 , enantiomerically pure 5(R)-HETE and 5(S)-HETE standards were measured at nominal retention times of 3.0 and 5.0 minutes, respectively, while a racemic mixture of 5(±)-HETE showed nearly equivalent measured peak areas between the enantiomers. Analyses of 5 representative plasma samples selected from the highest quartiles of 5-HETE levels in WHI showed generally similar 5(S) and 5(R) peak areas, suggesting that the WHI plasma measured levels of 5-HETE are a mixture of R-and S-enantiomers, in similar proportions.
Finally, we sought to test the generalizability of our findings in a new independent cohort, PREDIMED, that included both men and women and used a combined CVD end point of incident myocardial infarction, stroke, and CHD death (230 cases) in a case-cohort design. Two of the 4 LC-MS methods done in the same laboratory used to profile the WHI data had been applied to PREDIMED, allowing us to test 4 of the 8 validated metabolites (glutamine, glutamate, C34:2 hydroxy-PC, and C36:4 hydroxy-PC). Baseline characteristics of the PREDIMED validation cohort are shown in Table IV in the online-only Data Supplement. For the combined CVD outcome in men and women, 3 of the 4 metabolites (both hydroxy-PCs and glutamate) replicated, whereas glutamine did not (Table 3 ). All the relationships were 
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stronger for women, with only glutamate remaining significant in men alone. An interaction term indicated the significant effect modification by sex for both hydroxy-PCs (P for interaction <0.001). In a sensitivity analysis using CHD cases only (74 cases), the hazard ratio for C34:2 hydroxy-PC was 1.56 (95% confidence interval, 1.09-2.24), P=0.02. For C36:4 hydroxy-PC, the CHD-only hazard ratio was 1.59 (1.10-2.30), P=0.01. In a corresponding analysis using stroke cases only (115 cases), the hazard ratio for C34:2 hydroxy-PC was 1.48 (1.13-1.92), P=0.004, and for C36:4 hydroxy-PC, the hazard ratio was 1.34 (1.02-1.77), P=0.036.
DISCUSSION
In our study of the association of metabolites with CHD in postmenopausal women, we identified and validated 8 metabolites associated with future CHD in women. These metabolites included glutamine, glutamate, cytidine monophosphate, and 5 oxidized lipids that had not previously been associated with incident CHD in humans. The strongest associations with CHD were observed for the oxidized lipids including 2 species of hydroxy-PCs (C34:2 and C36:4) and 3 oxidized derivatives from arachidonic acid (15-HETE, 5-HETE, and 11-HETE). The hydroxy-PCs were also externally validated for CVD, CHD, and stroke in an external population (PREDIMED), with stronger associations seen in women. Arachidonic acid-derived HETEs have previously been associated with atherosclerosis, but not previously with incident CHD. A previous study by Oni-Orisan et al 30 found an association between higher levels of 11-HETE and 15-HETE and extent of prevalent coronary artery disease. 5-HETE, 12-HETE, and 15-HETE are wellcharacterized products of 5-, 12-, and 15-lipoxygenase activity, respectively. 5-Lipoxgenase (ALOX5) activity is essential for leukotriene biosynthesis and is therefore linked to a number of inflammatory pathologies. 
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However, when mono-HETEs are produced by these enzymes, the stereochemistry of the hydroxyl bound carbon is in the S-configuration. Our analyses found that the HETEs associated with CHD appeared to be produced from oxidative stress. This is the first report of an association between nonenzymatically generated mono-HETEs and incidence of CHD. We also identified 2 novel oxidized phospholipids, C34:2 hydroxy-PC and C36:4 hydroxy-PC, associated with CHD. C34:2 hydroxy-PC was the metabolite most strongly associated with CHD in our cohort, with a >4-fold increased risk of CHD for women in the highest quartile. This association was robust across all strata tested, including whether or not aspirin and statins were used, or whether there was baseline diabetes mellitus or obesity. In PREDIMED, where the majority of incident CVD cases were in men, C34:2 hydroxy-PC was validated as significantly associated with CVD, and with CHD and stroke. When examined by sex, women had a significant 79% increased risk of CVD per SD of C34:2 hydroxy-PC, but results were nonsignificant in men, despite fewer CVD events occurring in women, and the sex-by-metabolite interaction term was significant. Similar associations were observed for C36:4 hydroxy-PC. No antioxidants were added to the samples to prevent ex vivo oxidation in either of the studies. Whether these biomarkers remain more strongly associated with CVD in women in other populations requires further exploration, as do the underlying mechanisms.
The dysregulated oxidized lipids (HETEs and hydroxyPCs) associated with CHD may offer new markers of oxidation and risk. They were not correlated with other biomarkers measured (ρ<0.2) including inflammation markers, traditional lipids, body mass index, and systolic blood pressure, but are strongly associated with each other, as illustrated in the network analysis, and weakly associated with the other metabolites. From the stereoisomer analysis, the mono-HETE profiles are consistent with a nonenzymatic oxidative mechanism, which could also include generation of the hydroxyPCs. Although we were unable to assess replication of the HETEs in the PREDIMED because of the lack of available data on this class of metabolites, the strong replication of the hydroxy-PCs, along with the strong correlation between the hydroxy-PCs and the HETEs, suggests that the HETEs are likely to replicate as well. Lipid oxidation has been extensively studied in the context of model systems of overt atherosclerotic lesions. 31 Demonstration of the relationship between significantly dysregulated oxidized lipids and cardiovascular outcomes in longitudinal human cohort studies has been more difficult, but some associations with CHD outcomes 32, 33 and mortality 34 have been shown. In addition, a recent study of plasma metabolites of patients with existing CHD in comparison with healthy controls also identified lipid peroxidation-related metabolites, including 5-HETE. 35 Our data support the hypothesis that early mechanisms involving lipid oxidation, for which these metabolites may be part of the cause or a consequence, may contribute to the etiology of CHD years before an event.
Our results are also not inconsistent with prior studies focusing narrowly on lipidomics. Both triacylglycerols and diacylglycerols were associated with CHD in our sample, although the association was eliminated after adjustment for total and high-density lipoprotein cholesterol. Using a lipidomics platform, Stegemann et al 7 found that C54.2 triacylglycerol was associated with increased risk of CHD in the Bruneck Study, with validation in Twins UK. Methods between their study and ours differed in the metabolites measured; in addition, our study included an increased number of cases for discovery and exclusively included women for the discovery and validation sets. We did replicate the C54:2 triacylglycerol finding, although not after adjustment for traditional risk factors, but did not find a significant association for C16:1 cholesterol ester, C36:5 phosphatidylethanolamine, or C18:1 cholesterol ester. Alshehry et al 36 also found multiple lipids associated with future cardiovascular disease in a population with type 2 diabetes mellitus. Of these, we found similar nominal associations for C16:0 ceramide(d18:1), C22:0 ceramide(d18:1), C40:6 phosphatidylcholine, and C56:6 triacylglycerol. 
Direct associations for glutamate and inverse associations for glutamine, initially identified by similar metabolomic profiling, have been consistently reported for both CHD and diabetes mellitus. 4, 6, 9, 37 Cheng et al 37 found that glutamate and glutamine were associated with markers of glucose metabolism as well as incident diabetes mellitus and showed that glutamine supplementation improved glucose tolerance in mice. A glutamic acid-related polymorphism has also been related to a higher risk of incident CHD among diabetic patients. 38 Other metabolomic studies have also found associations of glutamate and glutamine with CHD, including 2 studies primarily in men, 6, 9 and one that replicated the association in samples with both men and women. 4 Trimethylamine N-oxide, choline, and branched chain and aromatic amino acids previously identified as associated with increased CHD risk were not selected by using the data-driven approach of our study. Trimethylamine N-oxide and choline were not nominally significant in this cohort of women (Table I in Other studies have reported higher branch chain amino acid levels in men than women, 14 and in a prespecified PREDIMED analysis combining men and women, branched chain amino acid levels were associated with CVD events. 39 We did identify a relationship between risk of CHD and isocitrate in matched analyses, but other branched chain amino acids were not associated with CHD in our cohort. Isocitrate was inversely associated with longevity and positively associated with cardiovascular disease as reported by Cheng et al 11 in an analysis also using the Framingham data set.
Our study has several strengths, including a wellvalidated metabolomics platform, detailed covariate information, a large number of carefully adjudicated end points, and a robust methodology. In addition, the study provides a detailed look at metabolomics and CHD in women, which has previously been lacking. Our results did replicate the similarly aged women of the PREDIMED study, where the mean body mass index was similar. Although the generalizability beyond these postmenopausal women remains to be seen, these women are representative of the current population body mass index and, importantly, represent a group of women at high risk of CHD. Additional data will also be needed to identify whether these results are specific to women of menopausal status or whether there is a smaller effect in men, as seen in the PREDIMED data.
CONCLUSIONS
In 2 separate sets of postmenopausal women, multiple metabolites associated with CHD risk were identified and validated. These metabolites included novel metabolites, such as hydroxy-PCs and HETEs, and glutamate and glutamine, which have been consistently identified in other populations. The strongest marker, C34:2 hydroxy-PC, further replicated in a third set of women and men, with a suggestion of an interaction by sex. Overall, the strong association of oxidized phospholipids (hydroxy-PCs and HETEs) with CHD supports additional investigation of the mechanism and potential clinical use of oxidative risk. Further evaluation of these markers in other populations, and more detailed biological inquiry, is warranted.
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